Biohaven Pharmaceutical (BHVN) Stock Forecast, Price Target & Predictions
BHVN Stock Forecast
Biohaven Pharmaceutical stock forecast is as follows: an average price target of $59.33 (represents a 65.96% upside from BHVN’s last price of $35.75) and a rating consensus of 'Buy', based on 12 wall street analysts offering a 1-year stock forecast.
BHVN Price Target
The average price target for Biohaven Pharmaceutical (BHVN) is $59.33 based on 1-year price targets from 12 Wall Street analysts in the past 3 months, with a price target range of $65.00 to $55.00. This represents a potential 65.96% upside from BHVN's last price of $35.75.
BHVN Analyst Ratings
According to 12 Wall Street analysts, Biohaven Pharmaceutical's rating consensus is 'Buy'. The analyst rating breakdown for BHVN stock is 0 'Strong Buy' (0.00%), 12 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Biohaven Pharmaceutical Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Dec 04, 2024 | Leonid Timashev | RBC Capital | $61.00 | $46.58 | 30.97% | 70.63% |
| Oct 15, 2024 | Jason Gerberry | Bank of America Securities | $65.00 | $52.77 | 23.18% | 81.82% |
| Sep 24, 2024 | Marc Goodman | Leerink Partners | $60.00 | $44.22 | 35.69% | 67.83% |
| Sep 24, 2024 | Douglas Tsao | H.C. Wainwright | $59.00 | $45.94 | 28.43% | 65.03% |
| Sep 24, 2024 | Jason Gerberry | Bank of America Securities | $62.00 | $45.94 | 34.96% | 73.43% |
| Sep 24, 2024 | Leonid Timashev | RBC Capital | $68.00 | $45.94 | 48.02% | 90.21% |
| Sep 23, 2024 | Thomas Shrader | BTIG | $59.00 | $46.56 | 26.72% | 65.03% |
| Sep 23, 2024 | Brian Skorney | Robert W. Baird | $60.00 | $46.56 | 28.87% | 67.83% |
| Sep 16, 2024 | Amy Li | Jefferies | $57.00 | $38.08 | 49.68% | 59.44% |
| Sep 04, 2024 | William Pickering | Tudor Pickering | $55.00 | $38.17 | 44.09% | 53.85% |
| Jul 24, 2024 | Terence Flynn | Morgan Stanley | $58.00 | $37.81 | 53.40% | 62.24% |
| May 29, 2024 | Brian Skorney | Robert W. Baird | $58.00 | $30.31 | 91.36% | 62.24% |
| May 29, 2024 | Leonid Timashev | RBC Capital | $59.00 | $28.69 | 105.65% | 65.03% |
| Jan 04, 2023 | J.P. Morgan | $23.00 | $13.50 | 70.37% | -35.66% | |
| Dec 02, 2022 | BTIG | $24.00 | $16.53 | 45.19% | -32.87% |
The latest Biohaven Pharmaceutical stock forecast, released on Dec 04, 2024 by Leonid Timashev from RBC Capital, set a price target of $61.00, which represents a 30.97% increase from the stock price at the time of the forecast ($46.58), and a 70.63% increase from BHVN last price ($35.75).
Biohaven Pharmaceutical Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 1 | 2 | 13 |
| Avg Price Target | $61.00 | $63.00 | $60.08 |
| Last Closing Price | $35.75 | $35.75 | $35.75 |
| Upside/Downside | 70.63% | 76.22% | 68.06% |
In the current month, the average price target of Biohaven Pharmaceutical stock is $61.00, according to 1 Wall Street analyst offering twelve months forecast. The average price target represents a 70.63% increase as opposed to Biohaven Pharmaceutical's last price of $35.75. This month's average price target is down -3.17% compared to last quarter, and up 1.53% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Dec 04, 2024 | RBC Capital | Outperform | Outperform | Hold |
| Nov 13, 2024 | Cowen & Co. | Buy | Buy | Hold |
| Oct 15, 2024 | Bank of America Securities | Buy | Buy | Hold |
| Sep 24, 2024 | Leerink Partners | Outperform | Outperform | Hold |
| Sep 24, 2024 | Bernstein | Outperform | Outperform | Hold |
| Sep 24, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Sep 24, 2024 | Bank of America Securities | Buy | Buy | Hold |
| Sep 24, 2024 | RBC Capital | Outperform | Outperform | Hold |
| Sep 23, 2024 | Cowen & Co. | Buy | Buy | Hold |
| Sep 23, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Sep 23, 2024 | BTIG | Buy | Buy | Hold |
| Sep 16, 2024 | Jefferies | Buy | Initialise | |
| Sep 04, 2024 | Bernstein | Outperform | Initialise | |
| Jul 24, 2024 | Morgan Stanley | Overweight | Initialise | |
| Jun 25, 2024 | Cowen & Co. | Buy | Buy | Hold |
| May 29, 2024 | RBC Capital | Outperform | Outperform | Hold |
| May 28, 2024 | Cowen & Co. | Buy | Buy | Hold |
| Apr 23, 2024 | UBS | Buy | Buy | Hold |
| Apr 15, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Dec 02, 2022 | BTIG | Buy | Initialise | |
| Oct 26, 2022 | Cantor Fitzgerald | Overweight | Upgrade |
Biohaven Pharmaceutical's last stock rating was published by RBC Capital on Dec 04, 2024. The company gave BHVN a "Outperform" rating, the same as its previous rate.
Biohaven Pharmaceutical Financial Forecast
Biohaven Pharmaceutical Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Mar 23 | Dec 22 | Mar 22 | Mar 21 | Mar 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | $-215.08M | - | - | - |
| Avg Forecast | $31.61M | $27.68M | $23.49M | $19.58M | $5.57M | $2.70M | $2.50M | $2.50M | $11.11M | $1.67K | - | $318.71M | $289.74M | $204.23M | $263.40M | $36.41M | $877.31K |
| High Forecast | $31.61M | $27.68M | $23.49M | $19.58M | $5.57M | $2.70M | $2.50M | $2.50M | $11.11M | $1.67K | - | $382.46M | $347.69M | $245.07M | $316.08M | $43.69M | $1.05M |
| Low Forecast | $31.61M | $27.68M | $23.49M | $19.58M | $5.57M | $2.70M | $2.50M | $2.50M | $11.11M | $1.67K | - | $254.97M | $231.79M | $163.38M | $210.72M | $29.13M | $701.85K |
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 6 | 3 | - | 14 | 19 | 12 | 14 | 17 | 16 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | -1.05% | - | - | - |
Biohaven Pharmaceutical's average Quarter revenue forecast for Mar 23 based on 19 analysts is $289.74M, with a low forecast of $231.79M, and a high forecast of $347.69M. BHVN's average Quarter revenue forecast represents a -234.71% decrease compared to the company's last Quarter revenue of $-215.08M (Dec 22).
Biohaven Pharmaceutical EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Mar 23 | Dec 22 | Mar 22 | Mar 21 | Mar 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 6 | 3 | - | 14 | 19 | 12 | 14 | 17 | 16 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | $-76.13M | $-213.07M | $-89.52M | - | - |
| Avg Forecast | $22.31M | $19.54M | $16.58M | $13.82M | $3.93M | $1.91M | $1.76M | $1.76M | $7.84M | $1.18K | - | $-45.23M | $-41.12M | $-95.15M | $-37.38M | $-126.57M | $-108.89M |
| High Forecast | $22.31M | $19.54M | $16.58M | $13.82M | $3.93M | $1.91M | $1.76M | $1.76M | $7.84M | $1.18K | - | $-36.18M | $-32.89M | $-76.12M | $-29.90M | $-101.26M | $-87.11M |
| Low Forecast | $22.31M | $19.54M | $16.58M | $13.82M | $3.93M | $1.91M | $1.76M | $1.76M | $7.84M | $1.18K | - | $-54.27M | $-49.34M | $-114.18M | $-44.85M | $-151.88M | $-130.66M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.85% | 2.24% | 2.40% | - | - |
undefined analysts predict BHVN's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Biohaven Pharmaceutical's previous annual EBITDA (undefined) of $NaN.
Biohaven Pharmaceutical Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Mar 23 | Dec 22 | Mar 22 | Mar 21 | Mar 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 6 | 3 | - | 14 | 19 | 12 | 14 | 17 | 16 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | $-70.49M | $-201.11M | $-97.03M | - | - |
| Avg Forecast | $-138.39M | $-140.26M | $-142.48M | $-149.11M | $-158.83M | $-156.06M | $-157.49M | $-160.12M | $-151.14M | $-160.58M | $-156.29M | $-116.35M | $-105.77M | $-126.41M | $-96.16M | $-147.80M | $-118.99M |
| High Forecast | $-138.39M | $-140.26M | $-142.48M | $-149.11M | $-158.83M | $-156.06M | $-157.49M | $-131.74M | $-55.32M | $-160.58M | $-156.29M | $-93.08M | $-84.62M | $-101.13M | $-76.92M | $-118.24M | $-95.19M |
| Low Forecast | $-138.39M | $-140.26M | $-142.48M | $-149.11M | $-158.83M | $-156.06M | $-157.49M | $-185.46M | $-198.56M | $-160.58M | $-156.29M | $-139.62M | $-126.93M | $-151.70M | $-115.39M | $-177.36M | $-142.78M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.67% | 1.59% | 1.01% | - | - |
Biohaven Pharmaceutical's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. BHVN's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Biohaven Pharmaceutical SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Mar 23 | Dec 22 | Mar 22 | Mar 21 | Mar 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 6 | 3 | - | 14 | 19 | 12 | 14 | 17 | 16 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | $14.32M | $76.37M | $19.68M | - | - |
| Avg Forecast | $25.80M | $22.59M | $19.17M | $15.98M | $4.55M | $2.21M | $2.04M | $2.04M | $9.07M | $1.36K | - | $227.14M | $206.49M | $139.28M | $187.72M | $29.72M | $716.04K |
| High Forecast | $25.80M | $22.59M | $19.17M | $15.98M | $4.55M | $2.21M | $2.04M | $2.04M | $9.07M | $1.36K | - | $272.57M | $247.79M | $167.14M | $225.27M | $35.66M | $859.25K |
| Low Forecast | $25.80M | $22.59M | $19.17M | $15.98M | $4.55M | $2.21M | $2.04M | $2.04M | $9.07M | $1.36K | - | $181.72M | $165.20M | $111.42M | $150.18M | $23.77M | $572.83K |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.07% | 0.55% | 0.10% | - | - |
Biohaven Pharmaceutical's average Quarter SG&A projection for Mar 24 is $227.14M, based on 14 Wall Street analysts, with a range of $181.72M to $272.57M. The forecast indicates a 1486.09% rise compared to BHVN last annual SG&A of $14.32M (Mar 23).
Biohaven Pharmaceutical EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Mar 23 | Dec 22 | Mar 22 | Mar 21 | Mar 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 6 | 3 | - | 14 | 19 | 12 | 14 | 17 | 16 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | $-1.03 | $-3.32 | $-2.71 | - | - |
| Avg Forecast | $-1.47 | $-1.49 | $-1.51 | $-1.58 | $-1.68 | $-1.65 | $-1.67 | $-1.70 | $-1.60 | $-1.70 | $-1.78 | $-1.55 | $-1.41 | $-1.22 | $1.43 | $-1.57 | $-1.61 |
| High Forecast | $-1.47 | $-1.49 | $-1.51 | $-1.58 | $-1.68 | $-1.65 | $-1.67 | $-1.40 | $-0.59 | $-1.70 | $-1.78 | $-1.55 | $-1.41 | $-1.22 | $1.43 | $-1.26 | $-1.29 |
| Low Forecast | $-1.47 | $-1.49 | $-1.51 | $-1.58 | $-1.68 | $-1.65 | $-1.67 | $-1.97 | $-2.10 | $-1.70 | $-1.78 | $-1.55 | $-1.41 | $-1.22 | $1.43 | $-1.89 | $-1.93 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.73% | 2.72% | -1.90% | - | - |
According to undefined Wall Street analysts, Biohaven Pharmaceutical's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to BHVN previous annual EPS of $NaN (undefined).
Biohaven Pharmaceutical Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| XFOR | X4 Pharmaceuticals | $0.58 | $3.67 | 532.76% | Buy |
| INZY | Inozyme Pharma | $2.93 | $16.00 | 446.08% | Buy |
| CCCC | C4 Therapeutics | $3.87 | $16.00 | 313.44% | Buy |
| TERN | Terns Pharmaceuticals | $5.80 | $18.67 | 221.90% | Buy |
| APLS | Apellis Pharmaceuticals | $33.32 | $70.80 | 112.48% | Buy |
| IMNM | Immunome | $11.02 | $23.00 | 108.71% | Buy |
| AMLX | Amylyx Pharmaceuticals | $4.00 | $8.25 | 106.25% | Buy |
| DAWN | Day One Biopharmaceuticals | $12.67 | $24.00 | 89.42% | Buy |
| MREO | Mereo BioPharma Group | $3.81 | $6.75 | 77.17% | Buy |
| NRIX | Nurix Therapeutics | $19.57 | $32.67 | 66.94% | Buy |
| BHVN | Biohaven Pharmaceutical | $35.75 | $59.33 | 65.96% | Buy |
| AGIO | Agios Pharmaceuticals | $34.19 | $53.50 | 56.48% | Buy |
| RVMD | Revolution Medicines, Inc. Warrant | $44.39 | $65.67 | 47.94% | Buy |
| KYMR | Kymera Therapeutics | $40.82 | $58.60 | 43.56% | Buy |
| BPMC | Blueprint Medicines | $90.46 | $122.60 | 35.53% | Buy |